| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/22/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 06/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/25/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Other Events, Financial Sta...|
Docs:
|
"Form of Series C-1 warrant",
"Form of Series C-2 warrant",
"Form of Series D Pre-funded warrant",
"Form of Placement Agent warrant",
"Form of Amended and Restated Common Stock Purchase Warrant between Agile Therapeutics, Inc. and an institutional investor",
"Form of Amended and Restated Series A Common Stock Purchase Warrant between Agile Therapeutics, Inc. and an institutional investor",
"Form of Amended and Restated Series A Common Stock Purchase Warrant between Agile Therapeutics, Inc. and an institutional investor",
"Form of Amended and Restated Series A-1 Common Stock Purchase Warrant between Agile Therapeutics, Inc. and an institutional investor",
"Form of Amended and Restated Series A-2 Common Stock Purchase Warrant between Agile Therapeutics, Inc. and an institutional investor",
"Form of Amended and Restated Series B Common Stock Purchase Warrant between Agile Therapeutics, Inc. and an institutional investor" |
|
| 05/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/24/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 05/23/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/19/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/17/2023 |
8-K
| Other Events Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/27/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events, F... |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 0% stake in Agile Therapeutics, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/08/2023 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 6.3% stake in Agile Therapeutics, Inc. |
| 01/26/2023 |
8-A12G
| Form 8-A12G - Registration of securities [Section 12(g)]: |
| 01/26/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 01/26/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
|